The progressive nature of type 2 diabetes (T2D) means that insulin may become a necessary adjunctive treatment in order to meet glycaemic targets and reduce diabetic complications.
Those on basal insulin who do not meet HBA1C target goals within 12 months have an unlikely probability of doing so thereafter, thus highlighting the importance of timely intensification.
This webinar will discuss the progressive nature of T2D, potential patient barriers and key determinants when choosing an insulin treatment strategy. Current international guidelines for intensifying basal insulin and managing both perceived and actual risk of glycaemic control will be outlined and integrated into practical case studies.
Presenter
Dr Brandon Orr-Walker (MBCHB, FRACP)
Brandon is the Clinical Head of Endocrinology and Diabetes at Middlemore Hospital and also maintains a private practice at the Medical Specialists Group in Auckland.
He is the Immediate Past President of The New Zealand Society for the Study of Diabetes (NZSSD) and has served on numerous local, regional and national advisories including the NZ Guidelines Group, and provided clinical advice leading to the development of the Diabetes Care Improvement Packages (DCIP).
Presenter
Dr Bryan Betty (FRNZCGP)
Bryan is a Wellington-based GP, who was previously Deputy Medical Director for PHARMAC.
He is presently Medical Director of the Royal New Zealand College of General Practitioners. He is a practicing GP, who works in Cannons Creek, East Porirua - a suburb known for its high needs and social deprivation.
Bryan sits on the Board of Tu Ora Compass Health PHO and is on the National Diabetes Leadership Group.
